Food security includes not only the provision of basic foodstuffs to the population but also the guarantee of their quality and safety for the consumer. These criteria are essential for milk as the primary food product. The pathological processes, which are developed in the breast, harm the quality of milk, and the medical products used in their treatment, may affect the safety of this product. The article has represented the results of the bioregulatory approach in treating catarrhal mastitis in cows using medical products containing ultra-low doses of biologically active substances. These products do not have a withdrawal period regarding milk. The use of this approach makes it possible to increase the safety of treatment, which in turn will lead to economic benefits. Clinical symptoms of mastitis were determined by clinical signs (increasing local temperature, soreness, thickening of the udder, changing in color and consistency of milk, presence of flakes and clots). A сow No. 3095 was selected with characteristics of clinical symptoms of catarrhal mastitis of the rear left lobe of the udder. The following scheme was used for therapy: intramuscular injection of Traumeel 10 ml once a day, intracisternal injection of Lachesis Сompositum 10 ml into the affected part once a day, Traumeel(gel) locally after milking. The choice of bioregulatory preparations was based on the components and their action. On the third day, the cow's udder swelling decreased, local temperature normalized. The color and consistency of milk during control milking and its examination with the Avita diagnostic test showed an improvement from (+++) to (++). Complete clinical and laboratory recovery was diagnosed on the sixth day. A cow was returned to the general herd. Based on the treatment results, it can be concluded that this treatment scheme for catarrhal mastitis is effective. The absence of a withdrawal period regarding milk and the acceleration of recovery rates make it economically profitable.